CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Ferrous sulfate +1 moredrug
Likely dose
Ferrous sulfate 325 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05047211
NCT05047211Phase 4Completed

A Feasibility Trial of Intravenous Iron vs. Oral Iron Supplementation for the Treatment of Postpartum Anemia (IVIRONMAN)

The University of Texas Medical Branch, Galveston·interventional·Posted Sep 17, 2021·Updated Aug 29, 2023

In Brief

A Phase 4 clinical trial evaluating Ferrous sulfate and Iron dextran for Anemia, Iron Deficiency and Delivery Complication. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This trial will be a comparative pragmatic open label feasibility randomized controlled trial of oral daily versus IV iron in anemic postpartum patients. Two randomly assigned groups will be compared during the postpartum period: 1. Oral Iron group: Ferrous sulfate 325 mg (65 mg elemental iron) by mouth for a total of 6 weeks TID. IV placebo in sodium chloride 0.9% 500mL IV infusion will be given before discharge home over 1 hour preceded by placebo test dose IV infusion of 100mL 0.9% sodium chloride. 2. IV Iron group: Low molecular weight iron dextran (infed) 1000mg in sodium chloride 0.9% 500mL IV infusion over 1 hour preceded by test dose 25 mg IV low molecular weight iron dextran infusion in 100mL 0.9% sodium chloride. 2.1 Oral placebo will be given by mouth for a total of 6 weeks TID.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedSep 17, 2021
Enrollment StartOct 7, 2021
Primary CompletionMar 15, 2023
Study CompletionApr 15, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.8 years ago

Interventions

Ferrous sulfatedrug

one tablet 325 milligrams three times a day

Iron dextrandrug

1000 mg intravenous infusion